This medical condition has either been superseded or has become inactive
| Specific Conditions |
|
| Level of Evidence | Insufficient data (Category 4a) |
|
Intravenous immunoglobulin (IVIg) may be indicated in certain highly selected cases where other treatments have not been effective. Refer to the current product information sheet for further information. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. |
|
| Bibliography |
|---|
| Smith, A, Jackson, M, Wang, F, et al 2005, ‘Neutralisation of muscarinic receptor autoantibodies by intravenous immunoglobulin in Sjögren’s syndrome’, Human Immunology, vol. 66, no. 4, pp. 411–6. |